Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.